A forum chart colors two catalog names the same green: CJC-1295 with DAC and CJC-1295 without DAC. The caption treats them as one proven long-acting GH booster. You zoom in and notice the fine print on the second vial, then the everyday question sharpens. Are the human trial numbers people quote for CJC-1295 actually about the without-DAC form that many research catalogs sell?
What the published adult trials actually used
Teichman and colleagues reported two randomized, placebo-controlled ascending-dose studies in healthy adults of a long-acting GHRH analog called CJC-1295. After a single subcutaneous dose, mean GH rose for days and IGF-I stayed elevated for roughly a week or more, with an estimated half-life on the order of several days. That pharmacology matches a Drug Affinity Complex (DAC) designed to bind albumin and linger.
Ionescu and Frohman separately showed that pulsatile GH secretion can persist while CJC-1295 continuously stimulates the axis in healthy men. Again, the studied construct was the long-acting DAC form. Those papers answer a mechanism and safety-tolerance question in supervised volunteer settings. They do not approve a research vial for muscle, fat loss, sleep, or anti-aging use.
Why “without DAC” is not the same evidence
Catalog language that says CJC-1295 without DAC usually points to a shorter-acting modified GRF(1-29)-style peptide that lacks the albumin-binding extension. Public human trial reports for that without-DAC construct are not sitting next to the Teichman and Ionescu abstracts. Borrowing multi-day GH and IGF-I curves from DAC studies and pasting them onto a without-DAC listing is a category error: different half-life design, different exposure profile, different evidence file.
WADA S2 literacy on this site already notes how CJC-1295 shows up as a named example on prohibited-list documents. A prohibited-list mention is not a therapy label, and it does not prove that a without-DAC research listing inherits DAC-trial pharmacokinetics.
Approved GH-axis medicines and diagnostic agents come with indication text, manufacturing controls, and monitoring language. A research-catalog CJC-1295 without DAC listing does not restart those controls. If a social post collapses “DAC form raised IGF-I for days in volunteers” into “this without-DAC vial is the same proven stack,” ask which molecule was in the published arms.
What to do with the chart. Separate three layers: (1) DAC-form volunteer pharmacology from 2006, (2) whether any current clinician is using an authorized GH-related pathway for a documented problem, and (3) whether a without-DAC catalog photo is being sold as if it owned the DAC trial curves. For personal GH concerns, use primary-care or endocrinology pathways and open trial registries-not color-coded forum graphics.
Not medical advice.
Sources
- NCBI AbstractPlus: Teichman et al. CJC-1295 DAC adult GH/IGF-I trials (PMID 16352683)
- NCBI AbstractPlus: Ionescu and Frohman CJC-1295 DAC pulsatile GH study (PMID 17018654)
- Everyday Brief: WADA S2 context naming CJC-1295
Related reading
- How to read WADA S2 when ads name CJC-1295
- Ipamorelin secretagogue ads versus human trial evidence
- Macrilen adult growth-hormone stimulation testing
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-12 PT. Not medical advice.